<DOC>
	<DOCNO>NCT02238626</DOCNO>
	<brief_summary>This single center , randomize , double-blind , placebo-controlled , 6-month study design evaluate safety , tolerability clinical responsiveness MN-166/ibudilast ( 60 mg/day ) administer adjunct riluzole ( 100 mg/day ) 60 subject ALS . This study consist two treatment arm , MN-166 match placebo . Randomization occur 2:1 ratio ( MN- 166 : placebo ) . Duration Treatment : Screening Phase : 3 month ; Double-blind Phase : 6 month ; Open-label Phase 6 month ( placebo subject ) ; Follow-up Phase : 2 week last dose . During treatment phase , subject return clinic Months 3 6 telephoned staff Months 1,2,4 , 5 collect information side effect new concomitant medication . All subject ( subject complete Double-blind Phase subject complete Open-label Phase ) prematurely discontinue return follow-up visit approximately 2 week last dose study drug ass adverse event status document concomitant medication . Safety assess monitor record treatment-emergent adverse event ( TEAEs ) include serious adverse event ( SAEs ) discontinuation due TEAEs . Additional assessment include regular monitoring hematology , blood chemistry , urine value , regular measurement vital sign , ECGs , medical history , physical neurological examination .</brief_summary>
	<brief_title>Ibudilast ( MN-166 ) Subjects With Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Ibudilast</mesh_term>
	<criteria>Written inform consent obtain willing able comply protocol opinion Investigator . Male female subject age ≥ 18 80 year , inclusive Diagnosis familial sporadic ALS define El EscorialRevised ( 2000 ) research diagnostic criterion ALS [ Clinically Definite , Clinically Probable , ProbableLaboratorySupported ] Diagnosis ALS onset less equal 5 year first clinical weakness Slow vital capacity ≥ 60 % predict within 1 month prior Treatment Day 1 Currently stable dose riluzole least 30 day prior initiation study drug . Subjects currently take riluzole start 50 mg qd first 7 day follow 50 mg bid follow 21 day prior screen . Patients may screen time period start study drug stable dose riluzole . All female consider childbearing potential unless postmenopausal ( amenorrheic least 12 consecutive month , appropriate age group , without know suspected cause ) sterilize surgically ( i.e. , bilateral tubal ligation , total hysterectomy , bilateral oophorectomy , surgery least 1 month dose ) . Females childbearing potential must use effective method contraception throughout entire study period 30 day study drug discontinuation . Females must lactate pregnant Screening Baseline ( document negative betahuman chorionic gonadotropin [ ßhCG ] ( human chorionic gonadotropin [ hCG ] ) . A separate baseline assessment require negative screening pregnancy test obtain 72 hour first dose study drug . Males practice contraception follow : condom use contraception female partner . Able swallow study medication capsule . Subject willing able comply protocol assessment visit , opinion study nurse/coordinator Investigator . Has know allergy study drug excipients . Has receive 23valent pneumococcal vaccine within 4 year prior start clinical trial . Use tracheostomy , tracheostomy invasive mechanical ventilation [ TIMV ] . Greater 3 % predicted loss postdiagnosis vital capacity per month great 1 unit loss post diagnosis ALSFRSR total score per month [ exclusive loss due begin use assistive device ] Confirmed hepatic insufficiency abnormal liver function ( AST and/or ALT great 3 time upper limit normal range ) Renal insufficiency define serum creatinine great 1.5 time upper limit normal range Currently clinically significant psychiatric disorder dementia would preclude evaluation symptom . Has clinically significant medical condition ( ALS ) include follow : neurological , metabolic , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , urological disorder , central nervous system infection would pose risk subject participate study might confound result study . History malignancy &lt; 5 year prior sign inform consent , except adequately treat basal cell squamous cell skin cancer situ cervical cancer . ECG find QTcB prolongation &gt; 450 m male &gt; 470 m female screen History HIV ( human immunodeficiency virus ) , clinically significant chronic hepatitis , active infection Subject history stomach intestinal surgery condition could interfere judge Investigator interfere absorption , distribution , metabolism , excretion study drug . Subject history alcohol substance abuse ( DSMIVTR criterion ) within 3 month prior screen alcohol substance dependence ( DSMIVTR criterion ) within 12 month prior screen . Subject poor peripheral venous access limit ability draw blood judge Investigator . Currently participate , participate , study investigational market compound device within 3 month prior sign inform consent . Unable cooperate study procedure , unlikely adhere study procedure keep appointment , opinion Investigator . Advanced ALS group follow inclusion/exclusion early ALS subject exception follow : Inclusion criterion : Diagnosis ALS onset ≤10 year first clinical weakness On Noninvasive ventilator Noninvasive pressure [ PNIV ] volume [ VNIV ] cycle ventilation stable use ≥ 4 hour daily 1 month prior Treatment Day . Slow vital capacity ≥ 20 % predict ( Knudsen 1983 ) within 1 month prior Treatment Day 1 Able swallow study medication capsule gastrostomy tube access delivery content medication capsule . Exclusion criterion : Use tracheostomy , tracheostomy invasive mechanical ventilation [ TIMV ] . No rate progression exclusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>amyotrophic lateral sclerosis</keyword>
	<keyword>pharmacotherapy</keyword>
	<keyword>intervention</keyword>
	<keyword>prospective</keyword>
	<keyword>safety endpoint</keyword>
	<keyword>preliminary efficacy</keyword>
	<keyword>ibudilast</keyword>
</DOC>